Payment overview · 2025
General Payments
$38.54
2 reported records · 1 companies
Healthcare provider profile · identity verified
Andrew M Barclay, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WICHITA, KS · NPI 1346201357
Verified facts
What the public records show
CMS Open Payments records show Andrew M Barclay, MD received $38.54 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.54 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $38.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
60 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 144 |
| Losartan Potassium | Losartan Potassium | 551 | 114 |
| Omeprazole | Omeprazole | 489 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 104 |
| Metformin Hcl Er | Metformin Hcl | 369 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 62 |
| Potassium Chloride | Potassium Chloride | 308 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 298 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 53 |
| Simvastatin | Simvastatin | 258 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 238 | 62 |
| Lisinopril | Lisinopril | 227 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 42 |
| Furosemide | Furosemide | 201 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 200 | 41 |
| Meloxicam | Meloxicam | 194 | 42 |
| Alendronate Sodium | Alendronate Sodium | 192 | 34 |
| Allopurinol | Allopurinol | 189 | 45 |
| Gabapentin | Gabapentin | 189 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 152 | 31 |
| Prednisone | Prednisone | 143 | 79 |
| Sertraline Hcl | Sertraline Hcl | 140 | 27 |
| Alprazolam | Alprazolam | 137 | 25 |
| Azithromycin | Azithromycin | 130 | 82 |
| Warfarin Sodium | Warfarin Sodium | 126 | 18 |
| Trazodone Hcl | Trazodone Hcl | 113 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 111 | 23 |
| Eliquis | Apixaban | 109 | 15 |
| Glimepiride | Glimepiride | 108 | 17 |
| Lorazepam | Lorazepam | 108 | 19 |
| Lovastatin | Lovastatin | 102 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 20 |
| Bupropion Xl | Bupropion Hcl | 91 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 22 |
| Pregabalin | Pregabalin | 76 | 21 |
| Mirtazapine | Mirtazapine | 74 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 29 |
| Ozempic | Semaglutide | 69 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 16 |
| Carvedilol | Carvedilol | 65 | 14 |
| Tramadol Hcl | Tramadol Hcl | 63 | 19 |
| Atenolol | Atenolol | 61 | 13 |
| Cephalexin | Cephalexin | 61 | 40 |
| Famotidine | Famotidine | 61 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 54 |
| Amoxicillin | Amoxicillin | 59 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 14 |
| Estradiol | Estradiol | 57 | 12 |
| Baclofen | Baclofen | 55 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 29 |
| Levofloxacin | Levofloxacin | 52 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 13 |
| Bumetanide | Bumetanide | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 32 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Telmisartan | Telmisartan | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 23 |
| Primidone | Primidone | 41 | suppressed |
| Carisoprodol | Carisoprodol | 40 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Acyclovir | Acyclovir | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 34 |
| Fluconazole | Fluconazole | 38 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 20 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.54 · 2 records | GlaxoSmithKline, LLC. | AREXVY, BEXSERO, PENMENVY, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error